Cost-effectiveness of treatments for male infertility: A review

Christian Pavlovich, P. N. Schlegel

Research output: Contribution to journalArticle

Abstract

Background: An etiologic factor is found in a majority of male infertility cases. Treatment may be either targeted specifically at the diagnosis, or is nonspecific. Assisted reproduction (specifically intracytoplasmic sperm injection (ICSI)) is a nonspecific form of treatment used for couples with different male-factor diagnosis. The authors chose to evaluate the cost-effectiveness of specific treatments for male infertility relative to that of nonspecific alternative treatments. Methods: A review of cost-effectiveness literature on Medline (1966-present) was performed. Cost-effectiveness was defined as cost per delivery, and was directly determined for specific and idiopathic causes of male infertility, or appraised critically from published studies. Overall procedural costs and actual delivery charges were included in every estimate, which took into account the costs of multiple gestation pregnancies and their increased neonatal support expenditures. Results: Diagnosis-specific treatments are more cost-effective than initial treatment with assisted reproduction for varicocele-associated obstructive and endocrine causes of male infertility. Cost per delivery for varicocelectomy is $26,300 US (treatment-specific delivery rate [DR] = 15%), for microsurgical reconstruction is $25,745 US (DR = 47%), and for endocrine therapy for hypogonadotropic hypogonadism is $15,226 US (DR = 59%). Similar cost analyses show that ICSI, with or without sperm retrieval, costs between $70,000 and $90,000 per delivery (overall DR = 33%). Although idiopathic male infertility has no proven therapy, intrauterine insemination (IUI) and ICSI provide real, albeit costly, chances at conception for these patients. Conclusions: Specific treatment of reproductive tract obstruction was more effective and more cost-effective than sperm retrieval and ICSI. Varicocelectomy was more cost-effective than ICSI for varicocele-associated infertility. The high cost per delivery of ICSI indicates that ICSI should not be used as an initial treatment if other therapies are available.

Original languageEnglish (US)
Pages (from-to)40-46
Number of pages7
JournalAssisted Reproduction Reviews
Volume8
Issue number1
StatePublished - 1998
Externally publishedYes

Fingerprint

Male Infertility
Cost-Benefit Analysis
Intracytoplasmic Sperm Injections
Costs and Cost Analysis
Sperm Retrieval
Therapeutics
Varicocele
Reproduction
Multiple Pregnancy
Hypogonadism
Insemination
Health Expenditures
Health Care Costs
Infertility
Pregnancy

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Cost-effectiveness of treatments for male infertility : A review. / Pavlovich, Christian; Schlegel, P. N.

In: Assisted Reproduction Reviews, Vol. 8, No. 1, 1998, p. 40-46.

Research output: Contribution to journalArticle

@article{cbfe45598142428b9f7c07e826e8da2b,
title = "Cost-effectiveness of treatments for male infertility: A review",
abstract = "Background: An etiologic factor is found in a majority of male infertility cases. Treatment may be either targeted specifically at the diagnosis, or is nonspecific. Assisted reproduction (specifically intracytoplasmic sperm injection (ICSI)) is a nonspecific form of treatment used for couples with different male-factor diagnosis. The authors chose to evaluate the cost-effectiveness of specific treatments for male infertility relative to that of nonspecific alternative treatments. Methods: A review of cost-effectiveness literature on Medline (1966-present) was performed. Cost-effectiveness was defined as cost per delivery, and was directly determined for specific and idiopathic causes of male infertility, or appraised critically from published studies. Overall procedural costs and actual delivery charges were included in every estimate, which took into account the costs of multiple gestation pregnancies and their increased neonatal support expenditures. Results: Diagnosis-specific treatments are more cost-effective than initial treatment with assisted reproduction for varicocele-associated obstructive and endocrine causes of male infertility. Cost per delivery for varicocelectomy is $26,300 US (treatment-specific delivery rate [DR] = 15{\%}), for microsurgical reconstruction is $25,745 US (DR = 47{\%}), and for endocrine therapy for hypogonadotropic hypogonadism is $15,226 US (DR = 59{\%}). Similar cost analyses show that ICSI, with or without sperm retrieval, costs between $70,000 and $90,000 per delivery (overall DR = 33{\%}). Although idiopathic male infertility has no proven therapy, intrauterine insemination (IUI) and ICSI provide real, albeit costly, chances at conception for these patients. Conclusions: Specific treatment of reproductive tract obstruction was more effective and more cost-effective than sperm retrieval and ICSI. Varicocelectomy was more cost-effective than ICSI for varicocele-associated infertility. The high cost per delivery of ICSI indicates that ICSI should not be used as an initial treatment if other therapies are available.",
author = "Christian Pavlovich and Schlegel, {P. N.}",
year = "1998",
language = "English (US)",
volume = "8",
pages = "40--46",
journal = "Assisted Reproduction Reviews",
issn = "1051-2446",
publisher = "Decker",
number = "1",

}

TY - JOUR

T1 - Cost-effectiveness of treatments for male infertility

T2 - A review

AU - Pavlovich, Christian

AU - Schlegel, P. N.

PY - 1998

Y1 - 1998

N2 - Background: An etiologic factor is found in a majority of male infertility cases. Treatment may be either targeted specifically at the diagnosis, or is nonspecific. Assisted reproduction (specifically intracytoplasmic sperm injection (ICSI)) is a nonspecific form of treatment used for couples with different male-factor diagnosis. The authors chose to evaluate the cost-effectiveness of specific treatments for male infertility relative to that of nonspecific alternative treatments. Methods: A review of cost-effectiveness literature on Medline (1966-present) was performed. Cost-effectiveness was defined as cost per delivery, and was directly determined for specific and idiopathic causes of male infertility, or appraised critically from published studies. Overall procedural costs and actual delivery charges were included in every estimate, which took into account the costs of multiple gestation pregnancies and their increased neonatal support expenditures. Results: Diagnosis-specific treatments are more cost-effective than initial treatment with assisted reproduction for varicocele-associated obstructive and endocrine causes of male infertility. Cost per delivery for varicocelectomy is $26,300 US (treatment-specific delivery rate [DR] = 15%), for microsurgical reconstruction is $25,745 US (DR = 47%), and for endocrine therapy for hypogonadotropic hypogonadism is $15,226 US (DR = 59%). Similar cost analyses show that ICSI, with or without sperm retrieval, costs between $70,000 and $90,000 per delivery (overall DR = 33%). Although idiopathic male infertility has no proven therapy, intrauterine insemination (IUI) and ICSI provide real, albeit costly, chances at conception for these patients. Conclusions: Specific treatment of reproductive tract obstruction was more effective and more cost-effective than sperm retrieval and ICSI. Varicocelectomy was more cost-effective than ICSI for varicocele-associated infertility. The high cost per delivery of ICSI indicates that ICSI should not be used as an initial treatment if other therapies are available.

AB - Background: An etiologic factor is found in a majority of male infertility cases. Treatment may be either targeted specifically at the diagnosis, or is nonspecific. Assisted reproduction (specifically intracytoplasmic sperm injection (ICSI)) is a nonspecific form of treatment used for couples with different male-factor diagnosis. The authors chose to evaluate the cost-effectiveness of specific treatments for male infertility relative to that of nonspecific alternative treatments. Methods: A review of cost-effectiveness literature on Medline (1966-present) was performed. Cost-effectiveness was defined as cost per delivery, and was directly determined for specific and idiopathic causes of male infertility, or appraised critically from published studies. Overall procedural costs and actual delivery charges were included in every estimate, which took into account the costs of multiple gestation pregnancies and their increased neonatal support expenditures. Results: Diagnosis-specific treatments are more cost-effective than initial treatment with assisted reproduction for varicocele-associated obstructive and endocrine causes of male infertility. Cost per delivery for varicocelectomy is $26,300 US (treatment-specific delivery rate [DR] = 15%), for microsurgical reconstruction is $25,745 US (DR = 47%), and for endocrine therapy for hypogonadotropic hypogonadism is $15,226 US (DR = 59%). Similar cost analyses show that ICSI, with or without sperm retrieval, costs between $70,000 and $90,000 per delivery (overall DR = 33%). Although idiopathic male infertility has no proven therapy, intrauterine insemination (IUI) and ICSI provide real, albeit costly, chances at conception for these patients. Conclusions: Specific treatment of reproductive tract obstruction was more effective and more cost-effective than sperm retrieval and ICSI. Varicocelectomy was more cost-effective than ICSI for varicocele-associated infertility. The high cost per delivery of ICSI indicates that ICSI should not be used as an initial treatment if other therapies are available.

UR - http://www.scopus.com/inward/record.url?scp=0031905876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031905876&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031905876

VL - 8

SP - 40

EP - 46

JO - Assisted Reproduction Reviews

JF - Assisted Reproduction Reviews

SN - 1051-2446

IS - 1

ER -